Company intelligence / Profile preview

Latent Strategies

London, England, United Kingdomlatentstrategies.com ↗

Ownership: Private
Development stage: Other

Overview

Latent Labs has developed a generative AI platform that allows biotech and pharma companies to computationally design novel proteins—such as antibodies or enzymes—with improved properties. The company validates its models experimentally in-house but does not have its own clinical pipeline. Instead, it accelerates R&D timelines for partners by enabling rapid protein engineering. No direct clinical results are reported.

Modalities: AntibodyEnzymeProtein
Industry: Drug Discovery Services

Partnerships

Amazon Web Services (AWS)

Beyond the preview

Go deeper on Latent Strategies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Latent Strategies.

Explore the full profile